KRAS and colorectal cancer: This study displayed a significantly lower rate of KRAS wild‐type in pancreatic body/tail cancers than pancreatic head cancers, indicating a low efficiency of regorafenib, panitumumab and cetuximab, which are FDA‐approved drugs for the treatment of colorectal cancer patients with KRAS wild‐type.